TF and neoplasm: This yields an apparent difference in the tumor-to-background ratio between LS301 and AF-Tf at 24 h, with a statistically significant difference at 48 h postinjection (p<0.05), which is in agreement with the ex vivo results [Figs. 6(d), 6(h), 6(l), and 6(p)].